';
side-area-logo

ABOUT US

VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.

VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.

The Company’s lead product candidate, oral VXM01, activates killer T-cells targeting tumor vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors.

VXM01 is currently in clinical development for several tumor types, including pancreatic, colorectal and brain cancer.

The Company has several additional product candidates at various stages of preclinical development targeting a variety of tumor targets and neoantigens.

VAXIMM has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate avelumab, a human anti-PD-L1 antibody, in combination with VXM01 in glioblastoma and colorectal cancer. The Company also has entered into a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs.

VAXIMM’s investors include BB Biotech Ventures, BioMed Partners, CMS, M Ventures and Sunstone Capital.

VAXIMM AG is headquartered in Basel, Switzerland.  Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities.

Management Team

VAXIMM has a strong management team of experienced leaders with outstanding scientific knowledge and medical development expertise.

Thomas Hecht Chairman VAXIMM Supervisory Board
Thomas Hecht, MD
Executive Chairman
Thomas Hecht, MD, Chairman, is a seasoned manager and has extensive experience in the biopharmaceutical industry. Dr. Hecht is founder and owner of Hecht Healthcare Consulting, which provides marketing, clinical development and mergers & acquisitions services to the pharmaceutical/biotechnology industry. Previously, he was VP Marketing (Hematology, Oncology, New Products) at Amgen Europe. Before that, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen Europe. He currently serves as Chairman of the Boards of Affimed N.V. and Aelix Therapeutics S.L. and as Board Member of Cell Medica Ltd. He was previously Chairman of the Boards of ESBATech AG (acquired by Alcon/Novartis in 2009), SuppreMol GmbH (acquired by Baxalta in 2015) and Cytos AG and Member of the Board of Humabs BioMed AG (acquired by Vir Biotechnology in 2017). Prior to joining the biopharmaceutical industry, Dr. Hecht was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
Heinz Lubenau Managing Director VAXIMM
Heinz Lubenau, PhD
Chief Operating Officer & Co-Founder
Heinz Lubenau co-founded VAXIMM in 2008. Prior to this, 2003-2008, he was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at BioGeneriX AG, where he led the development work of the first biosimilar G-CSF Ratiograstim® from preclinical studies through European marketing approval and launch and of the second-generation G-CSF Lonquex from project implementation to clinical Phase II. In 1994, he joined Servier and rose to Clinical Research Manager and Project Director Internal Medicine in 2001. In this role he was responsible for Servier Phase I to Phase III clinical trials in Germany, Austria and Switzerland for various indications. Dr. Lubenau has a PhD in pharmacy from Johannes-Gutenberg-University, Mainz.
Image
Marc Mansour, PhD, MBA
Chief Scientific Officer & Chief Business Officer
Marc Mansour joined VAXIMM in September 2016 with over 15 years of experience in biotech R&D and management. He was previously with Immunovaccine, Inc., a publicly traded Canadian company focused on developing cancer immunotherapies and infectious disease vaccines, for thirteen years. There, he served in positions of increasing responsibility, including Chief Scientific Officer, and, ultimately, Chief Executive Officer. He has strong expertise in vaccines and the early clinical development of immuno-oncology products. He has published a number of articles in peer-reviewed journals and holds several patents. Dr. Mansour has a PhD in biology from Dalhousie University and an MBA from the Sobey School of Business.
Image
Rainer Mück
Chief Financial Officer
As CFO of the Oerlikon Group, Rainer Mück was substantially involved in shaping the company’s new market profile. Before joining Oerlikon, he was responsible for international taxation at Commerzbank AG and head of General Electric’s German tax office and as such involved in a number of successful financial acquisitions and restructurings. He started his professional career as tax consultant in PriceWaterhouseCoopers’ international tax office and specialized in M&A and international taxation.
Rainer Mück graduated from Otto-Friedrich-University Bamberg and holds a degree in business administration. He worked as a lecturer for business taxation at the Frankfurt School of Finance and Management in Frankfurt/Main and lectured on a variety of fiscal topics. Rainer Mück was also chairman of the tax commitee of the American Chamber of Commerce in Germany and as such represented foreign interests in Germany. He is a member of various supervisory boards in German und Swiss Corporations.

Supervisory Board

Thomas Hecht Chairman VAXIMM Supervisory Board
Thomas Hecht, MD
Chairman
Thomas Hecht, MD, Chairman, is a seasoned manager and has extensive experience in the biopharmaceutical industry. Dr. Hecht is founder and owner of Hecht Healthcare Consulting, which provides marketing, clinical development and mergers & acquisitions services to the pharmaceutical/biotechnology industry. Previously, he was VP Marketing (Hematology, Oncology, New Products) at Amgen Europe. Before that, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen Europe. He currently serves as Chairman of the Boards of Affimed N.V. and Aelix Therapeutics S.L. and as Board Member of Cell Medica Ltd. He was previously Chairman of the Boards of ESBATech AG (acquired by Alcon/Novartis in 2009), SuppreMol GmbH (acquired by Baxalta in 2015) and Cytos AG and Member of the Board of Humabs BioMed AG (acquired by Vir Biotechnology in 2017). Prior to joining the biopharmaceutical industry, Dr. Hecht was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
Klaus Breiner Vice Chairman VAXIMM Supervisory Board
Klaus Breiner, PhD
Vice-Chairman
Klaus Breiner, PhD, Vice-Chairman is a Managing Partner at BB BIOTECH VENTURES. He co-founded VAXIMM and served as its Executive Chairman until 2016. Over the last two decades, Dr. Breiner has invested in a broad range of life science companies. Before becoming a venture capitalist, he was a business consultant with Booz Allen & Hamilton in Zurich, and a researcher at the Swiss Federal Institute of Technology (ETH) in Zurich and at the Center for Molecular Biology in Heidelberg (ZMBH). Dr. Breiner holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in molecular biology from the University of Heidelberg. Dr. Breiner’s past and present board assignments include Agendia BV, AM-Pharma BV, Alpex Pharma SA, Cadence Pharmaceuticals Inc. (now publicly listed), Glycart Biotechnology AG (acquired by Roche), Natural Dental Implants AG and Orthocon Inc.
Mathieu Simon VAXIMM Supervisory Board
Mathieu Simon, MD
Mathieu Simon, MD, is Venture Partner at B|B Pureos Bioventures Bellevue Venture Capital based in Zurich, Switzerland and Senior Strategic Advisor at Messier Maris & Associés, an international investment banking boutique. He previously served as Executive Vice President and Chief Operating Officer of Cellectis (NASDAQ: CLLS), one of the biopharmaceutical companies leading the development of next-generation CAR-T cell immunotherapies. He also was a member of Cellectis’ Board of Directors. Prior to joining Cellectis, he was Senior Vice President Head of Global Pharmaceutical Operations at Pierre Fabre SA. From 1994 to 2010, Dr. Simon served at Wyeth Pharmaceuticals in both senior corporate and regional roles in the US and Europe (Head of International Marketing and Medical Affairs and Managing Director of several Wyeth affiliates). Dr. Simon is an advisor to the European Commission D.G. Research and Innovation. Dr. Simon was certified in internal medicine at the Faculty of Medicine, Paris VII.
Image
Cheryl Zimberlin, PhD
Cheryl Zimberlin, PhD, is part of M Ventures, the corporate venture capital arm of Merck KGaA. M Ventures takes an active role in company creation and investment, with the mandate to invest in innovative technologies and products with the potential to significantly impact Merck‘s core businesses. Prior to joining the team, Dr. Zimberlin had a successful academic career at top-tier universities, publishing in major academic journals, including Nature. She holds a PhD in oncology and an MSc in biotechnology. Currently, she holds board positions in several M Ventures portfolio companies.
Image
Huaizheng Peng, PhD
Huaizheng Peng, PhD, serves as General Manager of International Investment and Operations for China Medical System Holdings, a specialty pharmaceutical company listed on the Hong Kong Stock Exchange. He is in charge of international operations for the company, including pharmaceutical asset acquisition/product licensing-in/out, international business development, outbound investment and asset management, among others. Dr. Peng previously was a partner of Northland Bancorp, a private equity firm. Before that, he worked as a head of life sciences and as a director of corporate finance at Seymour Pierce, a London-based investment bank and stockbroker. Earlier in his career, Dr. Peng was a senior portfolio manager, specialising in global life science and Asian technology investment at Reabourne Technology Investment Management Limited. Dr. Peng received a Bachelor´s degree in medicine from Hunan Medical College (now Central South University Xiangya School of Medicine) in Changsha, Hunan Province, China, and a Master´s degree in medicine from Hunan Medical College. Dr. Peng was awarded a PhD in molecular pathology from University College London (UCL) Medical School, London, UK and subsequently practiced as a clinical lecturer there.
Image
Markus Hosang, PhD
Dr. Hosang has a strong pharmaceutical and VC background and joined BioMedPartners in 2004 as a General Partner and Managing Director. Before he was a Venture Partner at MPM Capital, where he was co-responsible for their European deal flow, managed the European office in Munich, and served on the boards of several portfolio companies.

Prior to joining MPM in 2002, he was at Roche, where he served for nearly 20 years in several senior management positions in the global Pharma R&D organization, including VP and Director of the International Pharma Research Strategy Unit and Chief of Staff to the President of Roche Global R&D. He organized and served on the Global Board of R&D Directors and the Pharma Portfolio Board. Most recently he was VP and CSO of Genetics and Integrated Medicine and a member of the Roche Genetics Executive Committee.

Dr. Hosang received his M.S. and Ph.D. degrees in Biochemistry from the ETH in Zurich, and pursued his postgraduate training at Stanford University Medical School and at the University of Washington in Seattle. He currently serves as the Chairman of the Board of Directors of Unitectra AG, the joint technology transfer office of the Universities of Zurich, Bern and Basel.

Advisors

Jean-Paul Prieels VAXIMM Supervisory Board
Jean-Paul Prieels, PhD
Jean-Paul Prieels, PhD served as a Senior Vice President of Research and Development at GlaxoSmithKline Biologicals (now GSK Vaccines) until January 2011. He joined GlaxoSmithKline Biologicals in 1987 as an Associate Director R&D Projects Evaluation. His responsibilities gradually expanded to lead the global vaccine R&D development activities in Rixensart, Belgium. His career spans from basic research to process and product development. He was instrumental in developing several commercially available vaccines, such as rotavirus, human papilloma virus (HPV), pneumococcal conjugates and others. He serves as a member of the Independent Advisory Board for CureVac Inc. Since 2007, he has been a Member of the Scientific Advisory Board of the Singapore Bioprocessing Technology Institute. He serves as Chairman of the Board at Immune Health and he was also a Board member of Henogen from 2000 to 2008 (today Novasep).

Careers

To send your application please read the Data protection information for applications
as well as the Terms of Use and Privacy Policy
and confirm your acknowledgement by ticking the box: